

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. 355 (n) (4)

Peter Adamson, M.D.

Committee: The Pediatric Subcommittee of the Oncologic Drugs Advisory Committee

Meeting Date: March 14, 2006

I acknowledge that contingent upon public disclosure of self and imputed financial interests listed below, related to the discussions of clinical trials of methotrexate and daunomycin to be conducted under the Best Pharmaceuticals for Children Act. and Phase 4 requirements for Exjade (deferasirox). Methotrexate is sponsored by Mayne Pharma USA, a Mayne Group Ltd. Cerubidine (daunorubicin, daunomycin) is sponsored by Bedford Laboratories, a division of Ben Venue Laboratories, Inc., a wholly owned subsidiary of Boehringer Ingelheim Corporation, the U.S. affiliate of Boehringer Ingelheim GmbH, and Exjade is sponsored by Novartis Pharmaceutical Corporation, a subsidiary of Novartis AG, I am eligible to receive waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. 355(n)(4).

Type of Interest	Nature	Magnitude
Stock	Four Competitors	Each valued at less than \$5,001
Stock	Sponsor	Valued at less than \$5,001
Stock	Two Competitors	Each valued from \$5,001 to \$25,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests, waivers are not valid.

_____/s/_____
Signature of SGE

_____/2/8/06_____
Date